Advances in diagnosis of statin-induced liver injury
Received:March 01, 2016  Revised:May 26, 2016
View Full Text  View/Add Comment  Download reader
DOI:10.11915/j.issn.1671-5403.2016.09.0171
Key words:statins  liver injury  diagnosis
Author NameAffiliationE-mail
MA Ting-Ting, FAN Ying, ZHANG Yi-Na* Department of Geriatrics, the Second Affiliated Hospital, Harbin Medical University, Harbin 150001, China yinazhlu@163.com 
Hits: 1236
Download times: 1078
Abstract:
      Statins, a group of selective 3-hydroxy-3-methylglutaryl-coenzmye A (HMG-CoA) reductase inhibitors, are widely used in clinical practice as lipid lowering drugs to reduce cardiovascular events. However, after taking statins for some time, some patients may have elevated aminotransferases, hepatosplenomegaly, jaundice, and other clinical liver damaged manifestations, while others may be accompanied with asymptomatic elevated transaminases, increased direct bilirubin level, and prolonged prothrombin time. To a large extent, diagnosis of statin-induced liver injury (SILI) depends on the experience of clinicians, so missed diagnosis and misdiagnosis are common. In this article, we summarized the studies concerning SILI diagnosis to provide references for clinicians to improve diagnostic level.
Close